Abstract
Pathological response is postulated as a surrogate for survival in patients treated with neoadjuvant chemo-immunotherapy. In this sense, non-complete pathological response (non-CPR) patients present higher risk of disease progression compared to complete pathological responders (CPR). To identify gene expression patterns that may affect long-term outcomes in this high-risk group, we analysed surgical samples of non-CPR patients and characterized the differences between progressors and non-progressors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have